Read More
THE HADASSAH-UNIVERSITY Medical Center campus is seen in Ein Kerem.

Hadassah rolls out outpatient antibody cocktail infusion to reduce COVID

The treatment lasts around three hours, including observation.

Coronavirus: Antibody cocktail blocks symptomatic infections in trials

It is not a vaccine and is not expected to cause permanent immunity.

Sheba Medical Center team at the Coronavirus isolation ward of Sheba Medical Center unit, in Ramat G

Antibodies increase by 6 to 20 times after second Pfizer dose - Sheba

Results showed that antibodies were higher than those who suffered severe cases of the virus.

An illustration, created at the Centers for Disease Control and Prevention (CDC), depicts the 2019 N

Antibody study aims to protect those exposed to coronavirus from illness

Two studies will examine whether an antibody combination reduces the risk of developing COVID-19 and/or reduces the severity of the infection compared to a placebo.

Roche Diagnostics immunochemistry analyser

Moderna to use Roche antibody test in coronavirus vaccine trials

Roche’s Elecsys Anti-SARS-CoV-2 test US Food and Drug Administration (FDA) emergency use administration in May.

A medic of the regional hospital receives Russia's "Sputnik V" vaccine shot against the coronavirus

Coronavirus humoral immunity may decline in months after infection - study

Researchers called for a larger study of humoral immunity, saying that their small study emphasizes the need for further research.

Nano-vaccine mechanism of action

New study of Ebola may hold answers for long-term COVID-19 immunity

The study, carried out in a joint effort by British and Guinean scientists, is the world's largest and most comprehensive one to date to examine survivors of the Ebola virus.

Sheba Medical Center team at the Coronavirus isolation ward of Sheba Medical Center unit, in Ramat G

20% of verified coronavirus patients did not develop immunity

Bnei Brak serological survey shows at least 9% of city had corona

Tel Aviv U. researchers develop antibody cocktail against COVID-19

Lead scientist: ‘Asymptomatic patients may possibly contract disease a second time’

An individual dose of the filled SARS-CoV-2 vaccine candidate made by biotech company IDT Biologika

Israel Biological Institute ready to test coronavirus vaccine

The IIBR updated Gantz that it is prepared to begin the human testing phase of trials on October 21 and is waiting for approval from the Health Ministry's Helinski Committee.

Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy